BOSTON, November 7, 2017– The Institute for Clinical and Economic Review(ICER) is inviting applications for a new ICER Senior Visiting Fellowship. Selected fellows will receive financial support for six- to 12-month visits to work at the ICER headquarters in Boston.
We seek applications from all perspectives, including distinguished senior clinicians, policymakers, members of the patient community, academic research experts, public or private insurers, purchasers, and representatives from the life sciences industry.
“This new program affords us an exciting opportunity to bring fresh perspectives to ICER’s work and to stimulate the creation of a broader community of leaders in health technology assessment and evidence-based medical policy in the United States,” noted Steven D. Pearson, MD, MSc, ICER’s President.
While working with ICER, Fellows will connect with senior ICER staff to learn about ICER’s approach to health technology assessment and to share ideas for the future of the field. Fellows will also be assigned to work with one or more teams developing reviews on specific interventions.
Applications for the Senior Visiting Fellowship are due by January 15, 2018 for an anticipated start date any time between March and September 2018. Applications should include a CV and a two- to three-page personal statement describing relevant background and interests, what the applicant proposes to accomplish during the Fellowship, and the reasons why the applicant believes the ICER Fellowship will further his/her career and improve the effectiveness and value of the US health care system. Additional information about the application guidelines is available on ICER’s website.
Applications and any questions about the Fellowship should be directed to Beverly Andrade at email@example.com.
The Fellowship is supported by a grant from the Laura and John Arnold Foundation.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.